Hologic’s (HOLX) “Outperform” Rating Reaffirmed at William Blair

William Blair reaffirmed their outperform rating on shares of Hologic (NASDAQ:HOLX) in a research report sent to investors on Thursday morning,RTT News reports. William Blair also issued estimates for Hologic’s Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Several other equities analysts have also commented on HOLX. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group upped their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Down 10.1 %

Shares of NASDAQ:HOLX opened at $65.45 on Thursday. The firm has a fifty day moving average price of $72.63 and a 200 day moving average price of $77.86. Hologic has a 1-year low of $64.87 and a 1-year high of $84.67. The stock has a market cap of $14.77 billion, a P/E ratio of 19.65, a P/E/G ratio of 2.35 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Sell-side analysts predict that Hologic will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the third quarter worth about $25,000. General Partner Inc. bought a new stake in Hologic in the 4th quarter valued at $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares during the period. Finally, First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.